Clinton Group’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Clinton Group’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-16,754	Closed	-$248K	–	994
2017 Q1	$248K	Sell	16,754 -20,803	-55%	-$337K	0.01%	818
2016 Q4	$608K	Buy	+37,557	New	+$681K	0.04%	518
2016 Q3	–	Sell	-30,211	Closed	-$498K	–	1136
2016 Q2	$498K	Sell	30,211 -92,003	-75%	-$1.49M	0.02%	640
2016 Q1	$2.02M	Buy	122,214 +38,248	+46%	+$669K	0.12%	254
2015 Q4	$1.82M	Buy	83,966 +29,609	+54%	+$576K	0.15%	221
2015 Q3	$1.08M	Buy	+54,357	New	+$1.72M	0.1%	281

Other funds holding HZNP

SCM

Scopia Capital Management New York $112M AUM 48.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

BGIM

Brandywine Global Investment Management Philadelphia, Pennsylvania $14.9B AUM 20.41% 1-Year Est. Return

Clinton Group's HZNP Position: Q2 2017 in Review

Clinton Group sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q2 2017, closing a stake of 16,754 shares — an estimated $248K sold.

Clinton Group first reported a position in HZNP in Q3 2015 and held it in 6 quarters. The position peaked at $2.02M in Q1 2016. 190 funds tracked by Wall St. Rank hold HZNP as of Q2 2017.

Clinton Group reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q2 2017 after selling out during the quarter.
Clinton Group sold 16,754 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q2 2017, an estimated $248K.
Clinton Group first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2015 and held it in 6 quarters.
Clinton Group's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $2.02M in Q1 2016.
190 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q2 2017.

Based on Clinton Group's 13F filing for Q2 2017, filed 14 Aug 2017.